Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 15;105(1):35–46. doi: 10.1111/ejh.13405

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited European Journal of Haematology Published by John Wiley & Sons Ltd

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Differential activity of IRd and placebo‐Rd between patients with tumors with high vs low expression of c‐MYC, CD19, and CD81. While PFS with IRd did not differ significantly between these expression subgroups, PFS was significantly shorter with placebo‐Rd in patients with tumors expressing low vs high levels of CD19 and CD81. CI, confidence interval; HR, hazard ratio; IRd, ixazomib‐lenalidomide‐dexamethasone; PFS, progression‐free survival; Rd, lenalidomide‐dexamethasone [Colour figure can be viewed at wileyonlinelibrary.com]